Journal
BRITISH JOURNAL OF PSYCHIATRY
Volume 202, Issue 5, Pages 381-382Publisher
CAMBRIDGE UNIV PRESS
DOI: 10.1192/bjp.bp.112.121178
Keywords
-
Categories
Funding
- ECNP
Ask authors/readers for more resources
Anandamide is a ligand of the endocannabinoid system. Animals show a depletion following repeated Delta(9)-tetrahydrocannabinol (THC) administration but the effect of cannabis use on central nervous system levels of endocannabinoids has not been previously examined in humans. Cerebrospinal fluid (CSF) levels of the endocannabinoids anandamide, 2-arachidonoylglycerol (2-AG) and related lipids were tested in 33 volunteers (20 cannabis users). Lower levels of CSF anandamide and higher levels of 2-AG in serum were observed in frequent compared with infrequent cannabis users. Levels of CSF anandamide were negatively correlated with persisting psychotic symptoms when drug-free. Higher levels of anandamide are associated with a lower risk of psychotic symptoms following cannabis use.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available